 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ALD2510 / Alderaan Biotechnology
Selective depletion of regulatory T cells by ALD2510, a novel IL-2-sparing anti-CD25 antibody, synergizes with PD-1 blockade in breast and gynecologic cancers (Section 39; Poster Board #12) - Mar 14, 2023 - Abstract #AACR2023AACR_4698;
We collected public single-cell RNA/TCR-sequencing data from primary tumors and metastases of Triple-Negative Breast Cancer patients (TNBC, N = 28) biopsied before and after ?PD-1 (pembrolizumab). This study supports clinical evaluation of CD25high effector Tregs depletion by ALD2510 in patients with breast or gynecologic cancers resistant to PD-1 blockade.
- ALD2510 / Alderaan Biotechnology
Preclinical development of ALD2510, a Next-Gen Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors (Section 24; Poster Board #30) - Mar 14, 2023 - Abstract #AACR2023AACR_2615;
Noteworthy, strong TREG depletion was confirmed while CD4+ or CD8+ T-cells were not impacted, confirming ALD2510 selectivity for TREGS while sparing TCONV. This makes ALD2510 a promising candidate for the treatment of solid tumors, in particular those where the presence of TREGS in the TME is associated with worse prognosis and/or resistance to CPI.
- ALD2510 / Alderaan Biotechnology
ALD2510: Next Generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1642;
Conclusions ALD2510 is a next generation Fc-enhanced, T REG -selective and IL-2-sparing anti-CD25 mAb showing in vitro and in vivo efficacy , fully satisfactory safety and tolerability in NHP and excellent manufacturability. ALD2510 thus appears as a promising candidate for treatment of solid tumor patients, especially those suffering from gynecological malignancies, where highly immunosuppressive CD25 high T REGS were identified in the TME.
- ALD2510 / Alderaan Biotechnology
SELECTIVE TREG DEPLETION IN SOLID TUMORS WITH ALD2510, A NOVEL HUMANIZED CD25-SPECIFIC, IL-2 SPARING MONOCLONAL ANTIBODY. (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_608;
Conclusions This preclinical data package supports CD25 as a potent and selective Treg marker allowing Tregs depletion while sparing conventional T cells. In this context, ALD2510, a novel humanized CD25-specific and IL-2 sparing antibody presents all the required attributes for selective and efficient TIL-Tregs depletion, making it a promising drug candidate to treat a broad range of solid tumor patients.